EFIC-Grünenthal Grant: Improve the Understanding of Pain and its Therapy

AACHEN, Germany and BRUSSELS, November 19, 2012 /PRNewswire/ –

– Last call for 2012 applications at http://www.e-g-g.info

Unique funding opportunity for young scientists from across Europe! Young researchers
are invited to contribute with innovative research ideas and to apply for the
EFIC-Gruenenthal Grant (E-G-G) 2012, one of the most highly regarded grants worldwide in
the field of pain research. Provided by the European Federation of IASP(R) Chapters
(EFIC(R)) and the pharmaceutical company and pain expert Gruenenthal, this grant gives
young talented scientists the opportunity to translate their excellent ideas into clinical
research projects. Scientists can submit their research projects online at
http://www.e-g-g.info until the end of 2012.

Gruenenthal donates a total of EUR 200,000 for the biennial grant, which is shared
between the awarded scientists and is intended to support them early in their career. The
individual grants are valued at up to EUR 40,000 per project for a duration of up to two
years. The decision of the awards is made independently by the EFIC(R) Committee on
Research.

The EFIC Gruenenthal Grant aims at finding and supporting young pain researchers whose
work will define how we understand and treat pain in the future. Learn more about the
EFIC-Gruenenthal Grant on the E-G-G Youtube Channel
[http://www.youtube.com/user/EFICGruenenthalGrant ].

Guidelines, Quality Criteria and online application forms can be found at
http://www.e-g-g.info. Interested young scientists can submit their research projects
online by December 31st 2012.

About EFIC(R)

The European Federation of IASP(R) Chapters (EFIC(R)) is a multidisciplinary
professional organisation in the field of pain research and medicine, consisting of the 36
European chapters of the International Association of the Study of Pain (IASP(R)), which
are the IASP(R) accredited official pain societies in each country. Established in 1993,
EFIC’s constituent chapters represent pain societies from 36 European countries and close
to 20,000 scientists, physicians, nurses, physiotherapists, psychologists and other
healthcare professionals across Europe, who are involved in pain management and pain
research. More about EFIC: http://www.efic.org.

About Gruenenthal

The Gruenenthal Group is an independent, family-owned international research based
pharmaceutical company headquartered in Aachen, Germany. Building on its unique position
in pain, its objective is to become the most patient-centric company to be a leader in
therapy innovation. Gruenenthal is one of the last five research-oriented pharmaceutical
corporations with headquarters based in Germany which sustainably invests in research and
development. These investments amounted to about 25 % of revenues in 2011. Gruenenthal’s
research and development strategy concentrates on select fields of therapy and
state-of-the-art technologies. We focus on the intensive search for new ways to treat pain
better, more effectively and with fewer side-effects than before. Altogether, the
Gruenenthal Group has affiliates in 26 countries worldwide. Gruenenthal products are sold
in more than 155 countries and approx. 4,500 employees are working for the Gruenenthal
Group worldwide. In 2011, Gruenenthal reached estimated revenues of 947 Mio EUR. More
information: http://www.grunenthal.com.

        Gruenenthal Contact: Frank Schonrock, Vice President Corporate Communications
        Phone: +49-241-569-2161, Fax: +49-241-569-3539, frank.schoenrock@grunenthal.com
        Gruenenthal GmbH, 52099 Aachen, Germany, http://www.grunenthal.com

        EFIC(R) Contact: Christel Geevels, EFIC Executive Secretary
        Phone: +32(2)251-55-10, Fax: +32(2)251-48-10, christel.geevels@efic.org
        EFIC(R), Grensstraat 7 - mailbox 3, 1831 Diegem, Belgium, http://www.efic.org.

SOURCE Grunenthal GmbH